OraPointLab™ GC/MS (or LC/MS/MS) quantitative analysis delivers a legally defensible, scientific process. It is conducted on oral fluid / saliva taken at the same time as a sample for an on-site or lab-based screen.
It is recommended that GC/MS confirmatory testing be conducted for any non-negative result obtained by an on-site screen.
Only the specific drug class(s) indicated via an initial screen needs to be confirmed. For example, an OPIATE class non-negative screen result, would be followed by GC/MS testing for all OPIATE parent and metabolites drugs. A sample list of drugs and metabolites with Navignet3 established GC/MS processes is shown below. Please contact us for further information.
Reporting avialable via secure, encrypted INTERNET, eMail, Fax, & Phone.
Please Note: Should the GC/MS process detect a quantity of drug or drug metabolite at or above designate cut-off levels, it is recommended that an MRO process be intiated and a final "POSTIVE", or "NEGATIVE" result be determined.
|
OPIATES |
AMPHETAMINES |
|
Morphine |
Amphetamine (Dexedrine) |
|
6-AM |
Methamphetamine (Desoxyn) |
|
Codeine |
DMA (Love Pill) |
|
Dihydrocodiene |
MDEA (Eve) |
|
Hydrocodone (Vicodin, Lortab) |
MDMA (Ecstasy) |
|
Hydromorhone (Dilaudid) |
MARIJUANA |
|
Oxycodone (Oxycontin, Percoset) |
Delta-9-tetrahyrocannabinol CAS# 1972-08-3 |
|
Oxymorphone (Numorphan) |
COCAINE |
|
PCP |
Cocaine |
|
Phencyclidine (Angel Dust) |
Benzoylecgonine (BE) |
|
BENZODIAZEPINES |
BARBITURATES |
|
Aprazolam (Xanax) |
Amobarbital (Amytal) |
|
Chlordiazepoxide (Librium) |
Butabarbital (Butisol) |
|
Clonazepam (Klonopin) |
Butalbital (Fiorinal) |
|
Diazepam (Valium) |
Pentobarbital (Luminal) |
|
Lorazepam (Ativan) |
Seconbarbital (Seconal) |
|
Nordiazepam (Tranxene) |
PROXYPHENE |
|
Oxazepam (Serax) |
Propoxyphene (Darvon) |
|
Temazepam (Restoril) |
METHAQUALONE |
|
METHADONE |
Methaqualone |
|
Methadone |
|
|
EDDP |
|
|
EMDP |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 